CytRx Corp., a pharmaceutical research and development company that specializes in oncology, said in a release today that additional preliminary data from its Phase 2b clinical trial demonstrating aldoxorubicin’s potential advantage over doxorubicin in its efficacy of treatment of soft tissue sarcoma will be presented at the 18th Annual Connective Tissue Oncology Society (CTOS) Meeting. The presentation will be taking place next Thursday, October 31 at 4:30 p.m. Eastern time at the Sheraton New York Times Square Hotel.
Previous reports from the company said patients in the trial treated with aldoxorubicin had an Overall Response Rate (ORR) of 22%, while in contrast those administered the widely used chemotherapeutic agent doxorubicin had an ORR of 0%.
“Because CTOS draws thought leaders in the treatment of sarcoma from around the world, it provides an ideal forum to gain awareness of this compelling data and to acquaint the oncologists with our phase 3 study in patients with relapsed or refractory soft tissue sarcomas,” said CytRx President and CEO Steven A. Kriegsman. “Discoveries of new sarcoma treatments have been relatively few, particularly when compared with treatments for breast or prostate cancer, but the preliminary clinical results thus far drive our optimism that aldoxorubicin can fill an important medical need in patients with advanced soft tissue sarcoma.”
Soft tissue sarcoma is a cancer that occurs in muscle, fat, blood vessels, tendons, fibrous tissues, and connective tissue. It can arise anywhere in the body at any age. There are more than 30 types of this cancer, and more than 10,500 new cases are diagnosed each year in the U.S., according to statistics from the American Cancer Society.
In addition to the Phase 2b trial for soft tissue sarcoma treatment efficacy, CytRx has received permission from the U.S. Food and Drug Administration for conducting a Phase 2 clinical trial with aldoxorubicin in glioblastoma, a difficult-to-treat and deadly brain cancer. The company plans to conduct a Phase 2 clinical trial in HIV-related Kaposi’s sarcoma as well.
For more information, please visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
